Vivo Capital, LLC Unicycive Therapeutics, Inc. Transaction History
Vivo Capital, LLC
- $683 Million
- Q3 2024
A detailed history of Vivo Capital, LLC transactions in Unicycive Therapeutics, Inc. stock. As of the latest transaction made, Vivo Capital, LLC holds 4,470,152 shares of UNCY stock, worth $2.24 Million. This represents 0.27% of its overall portfolio holdings.
Number of Shares
4,470,152
Previous 3,470,152
28.82%
Holding current value
$2.24 Million
Previous $1.74 Million
5.59%
% of portfolio
0.27%
Previous 0.26%
Shares
2 transactions
Others Institutions Holding UNCY
# of Institutions
31Shares Held
46.8MCall Options Held
0Put Options Held
0-
Octagon Capital Advisors LP New York, NY8.56MShares$4.28 Million0.85% of portfolio
-
Great Point Partners LLC Greenwich, CT8.56MShares$4.28 Million1.62% of portfolio
-
Logos Global Management LP San Francisco, CA5.08MShares$2.54 Million0.28% of portfolio
-
Walleye Capital LLC Plymouth, MN5MShares$2.5 Million0.0% of portfolio
-
Silverarc Capital Management, LLC4MShares$2 Million0.41% of portfolio
About Unicycive Therapeutics, Inc.
- Ticker UNCY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,052,500
- Market Cap $7.53M
- Description
- Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...